SCM
PCVX icon

Soleus Capital Management’s Vaxcyte PCVX Stock Holding History

Soleus Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4M Sell
385,472
-223,486
-37% -$12.1M 0.91% 31
2025
Q4 		$28.1M Buy
+608,958
New +$27.2M 1.04% 26
2025
Q1 		– Sell
-99,050
Closed -$8.11M – 87
2024
Q4 		$8.11M Buy
99,050
+72,000
+266% +$7.15M 0.51% 46
2024
Q3 		$3.09M Sell
27,050
-158,200
-85% -$14.3M 0.24% 72
2024
Q2 		$14M Sell
185,250
-22,500
-11% -$1.53M 1.23% 30
2024
Q1 		$14.2M Sell
207,750
-207,700
-50% -$14.4M 1.05% 29
2023
Q4 		$26.1M Sell
415,450
-84,200
-17% -$4.37M 2.89% 13
2023
Q3 		$25.5M Sell
499,650
-71,600
-13% -$3.53M 2.35% 10
2023
Q2 		$28.5M Buy
571,250
+191,000
+50% +$9.05M 3.17% 9
2023
Q1 		$14.3M Sell
380,250
-7,700
-2% -$327K 1.48% 20
2022
Q4 		$18.6M Buy
387,950
+52,300
+16% +$2.05M 2.67% 12
2022
Q3 		$8.06M Sell
335,650
-35,000
-9% -$887K 1.09% 28
2022
Q2 		$8.06M Buy
370,650
+42,300
+13% +$979K 1.26% 28
2022
Q1 		$7.93M Buy
328,350
+33,600
+11% +$734K 1.02% 33
2021
Q4 		$7.01M Sell
294,750
-60,900
-17% -$1.42M 0.7% 31
2021
Q3 		$9.02M Sell
355,650
-20,000
-5% -$485K 1.41% 23
2021
Q2 		$8.46M Buy
375,650
+82,000
+28% +$1.68M 1.3% 22
2021
Q1 		$5.8M Buy
+293,650
New +$7.39M 1.05% 18

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soleus Capital Management's PCVX Position: Q1 2026 in Review

Soleus Capital Management reduced its Vaxcyte (PCVX) stake by 37% in Q1 2026, selling an estimated $12.1M and leaving 385,472 shares worth $22.4M. The position accounts for 0.91% of the portfolio, ranked #31.

Soleus Capital Management first reported a position in PCVX in Q1 2021 and has held it in 18 quarters since. The position peaked at $28.5M in Q2 2023. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Soleus Capital Management held 385,472 shares of Vaxcyte worth $22.4M as of Q1 2026.
  • Soleus Capital Management sold 223,486 Vaxcyte shares in Q1 2026, an estimated $12.1M.
  • Vaxcyte made up 0.91% of Soleus Capital Management's portfolio in Q1 2026, its #31 holding.
  • Soleus Capital Management first reported a position in Vaxcyte in Q1 2021 and has held it in 18 quarters since.
  • Soleus Capital Management's Vaxcyte position peaked at $28.5M in Q2 2023.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.